Skip to content
Screener

MiMedx Group MDXG Q2 2025 earnings

Reported July 30, 2025 · After market close

Revenue$98.6MBeat by $5.3M
EPS$0.10Beat by $0.04
Revenue estimate$93.3M
EPS estimate$0.06

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$69.6M
EPS estimate$0.01

Financials

Q2 2025

Income statement

See full
Revenue$98.6M+13.1%
Gross profit$79.9M+10.5%
Operating income$12.4M-47.2%
Net income$9.6M-45.4%
EPS (diluted)$0.06-50.0%

Balance sheet

See full
Cash & equivalents$118.9M+72.2%
Total debt$18.5M-4.1%
Total equity$216.6M+28.9%
Total assets$291.1M+26.5%

Cash flow

See full
Operating cash flow$14.4M-33.9%
CapEx$179.0K+70.5%
Free cash flow$14.2M-34.4%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$880.3M-13.9%
Enterprise value$779.9M-19.9%
P/E27.4×+15.9×
P/S2.4×-0.6×

Profitability

See full
Gross margin81.5%-2.0pp
Operating margin11.8%-10.1pp
Net margin8.8%-17.3pp
FCF margin15.7%+1.4pp

Returns & leverage

See full
Return on equity16.7%—
Debt / equity0.1×0.0×
Current ratio4.4×+0.5×

Segments

By product

See full
Wound$64.5M—
Surgical$34.1M—

FAQ

When did MiMedx Group report Q2 2025 earnings?
MiMedx Group (MDXG) reported Q2 2025 earnings on July 30, 2025 after market close.
What were MiMedx Group's Q2 2025 revenue and EPS?
MiMedx Group reported revenue of $98.6M and eps of $0.10 for Q2 2025.
Did MiMedx Group beat estimates in Q2 2025?
Revenue beat the consensus estimate of $93.3M by $5.3M. EPS beat the consensus estimate of $0.06 by $0.04.
How did MiMedx Group's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.1% from $87.2M a year earlier and eps grew 25.0% from $0.08.
Where can I find MiMedx Group's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001376339-25-000087) and the 10-Q periodic report (0001376339-25-000085) directly on SEC EDGAR. The filing index links above go to sec.gov.